Has Michael Levitt, MD received payments from drug or device companies?

Yes. Drug and device makers reported $178,976 in general payments to Michael Levitt, MD across 614 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Michael Levitt, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Michael Levitt, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Michael Levitt, MD

Hematology & Oncology · Manasquan, NJNPI 1891979381

Payments from drug & device makers

$178,976in general payments, 2019–2025

Across 614 payments — averaging $291.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

GSK$44K
Genentech, Inc.$28K
Amgen$28K
Takeda Pharmaceuticals U.S.A., Inc.$20K
Incyte Corporation$15K
Pharmacosmos Therapeutics Inc.$14K
plus $29K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
GSK	41	$44,236
Genentech, Inc.	2	$28,478
Amgen	44	$27,841
Takeda Pharmaceuticals U.S.A., Inc.	19	$19,756
Incyte Corporation	24	$14,909
Pharmacosmos Therapeutics Inc.	19	$14,335
Taiho Oncology, Inc.	17	$13,444
AstraZeneca(2 entities)	44	$4,225
E.r. Squibb & Sons, L.L.C.	48	$3,392
AVEO Pharmaceuticals, Inc.	2	$1,831
Exelixis Inc.	5	$722
Novartis	43	$715
Gilead(2 entities)	33	$549
Johnson & Johnson(2 entities)	28	$391
Merck	22	$334
Eisai Inc.	21	$330
AbbVie	18	$305
Seagen Inc.	17	$265
Genentech USA, Inc.	19	$253
Myriad Genetic Laboratories, Inc.	2	$209
Bristol Myers Squibb	12	$178
Lilly USA, LLC	13	$177
Bayer	7	$157
Rigel Pharmaceuticals, Inc.	9	$152
Stemline Therapeutics Inc.	8	$144
Pharmacyclics LLC, An Abbvie Company	3	$142
Daiichi Sankyo Inc.	7	$138
Astellas Pharma US Inc	9	$122
Mirati Therapeutics, Inc.	6	$112
Sanofi	5	$100
Puma Biotechnology, Inc.	6	$98
Pfizer	6	$92
EMD Serono, Inc.	5	$74
Beigene USA, Inc.	4	$62
Springworks Therapeutics, Inc.	3	$57
Regeneron Healthcare Solutions, Inc.	3	$47
Apellis Pharmaceuticals, Inc.	2	$37
Foundation Medicine, Inc.	2	$35
Geron Corporation	2	$34
Dendreon Pharmaceuticals LLC	2	$34
Agios Pharmaceuticals, Inc.	2	$33
Boehringer Ingelheim	2	$32
EUSA Pharma (US) LLC	2	$29
Myovant Sciences Inc.	2	$29
Teva Pharmaceuticals USA, Inc.	2	$29
Servier Pharmaceuticals LLC	2	$27
Acceleron Pharma, Inc.	2	$26
Beone Medicines USA, Inc.	1	$23
Karyopharm Therapeutics Inc.	1	$23
Array Biopharma Inc	1	$19
Sirtex Medical Inc	3	$18
Deciphera Pharmaceuticals Inc.	1	$17
Genmab U.S., Inc.	1	$16
ADC Therapeutics America, Inc.	1	$15
Mylan Institutional Inc.	1	$15
Ipsen Biopharmaceuticals, Inc	1	$15
Tesaro, Inc.	1	$15
Jazz Pharmaceuticals Inc.	1	$15
AMAG Pharmaceuticals, Inc.	1	$14
Epizyme, Inc.	1	$14

How this compares

$178,976 in reported general payments places this provider in the 85th percentile of 362 hematology & oncology providers in New Jersey.

See all hematology & oncology providers in New Jersey →

Medicare billing

Part B allowed, 2024

$304,832

Medicare patients

909

Services billed

2,250

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Manasquan

Carl HenningsonManasquan$349K
Bruno FangEast Brunswick$8.5M
Charles FarberMorristown$4.6M
Rajat BannerjiNew Brunswick$3.3M
Eleonora TeplinskyParamus$2.6M
Mohamad CherryMorristown$1.9M
Evan NaylorManahawkin$1.3M
James OrsiniBelleville$1.3M
Eli KirshnerWestwood$1.2M
Linda DanieuLivingston$1.2M

See the full list for New Jersey →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →